Summit Therapeutics falls after update on Akeso-partnered lung cancer trial
2026-05-01 09:59:22 ET
More on Summit Therapeutics
- Summit Therapeutics: It Still Feels Like The Market Got Ahead Of Itself
- Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
- Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Summit Therapeutics GAAP EPS of -$0.24 beats by $0.04
- Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season
Read the full article on Seeking Alpha
For further details see:
Summit Therapeutics falls after update on Akeso-partnered lung cancer trialNASDAQ: AKESF
AKESF Trading
-6.92% G/L:
$12.10 Last:
2,287 Volume:
$12.174 Open:



